Comparision of the efficacy of two kinds of antiviral drugs Adefovir and Entecavir

【Objective】To compare the efficacy and safety of antiviral drugs:Adefovir and Entecavir.【Method】 120 patients with chronic hepatitis B(CBV) were divided into two groups,one group was treated with Entecavir,another group was treated with Adefovir.Liver and kidney function,HBV DNA levels,hepatitis B virus serum markers of response effects and changes in blood analysis were observed after 4 weeks,12 weeks,24 weeks and 48 weeks respectively of the treatment.【Result】For the HBeAg-positive patients,the HBV DNA negative conversion rate in the Entecavir group was higher than that in the Adefovir group after 4 weeks,12 weeks,24 weeks,48 weeks of the treatment,and statistical analysis showed statistical significance(P 0.05).In the 4th week,the HBV DNA negative conversion rate of the Entecavir group was(33%),significantly higher than that of Adefovir group(0%)(P 0.01).However,the ALT normalization rate and the HBeAg seroconversion rate between the two groups had no significant difference(P 0.05);For HBeAg-negative patients,HBV DNA negative conversion rate of Entecavir group was superior to adefovir group(P 0.05),while the ALT normalization rate between the two groups had no significant difference(P 0.05).【Conclusion】Entecavir has significant anti-viral activity in the virological response in the treatment of CBV,which is particularly superior to Adefovir at the early stage.In the biochemical and immunological responses,entecavir is also higher than adefovir,but statistical analysis showed they have no significant difference.